US equities |
NVDA $237.03 ▲+1.32% SPCX $165.44 ▲+4.08% MU $1,058.35 ▼-1.54% TSLA $376.28 ▲+1.54% MSFT $527.87 ▲+2.00% INTC $115.90 ▼-2.87% SNDK $1,717.06 ▼-0.17% AMD $627.31 ▼-1.04%
FinancialContent

MAIA Biotechnology, Inc. Common Stock (NY:MAIA)

1.180 -0.010 (-0.84%)
Delayed Quote Updated: 10:02 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MAIA Biotechnology, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
MAIA Biotechnology Reveals New Clinical Data Showing THIO’s Strong Efficacy in Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology (MAIA) to Showcase Groundbreaking Telomere-Targeting Cancer Treatments at BIO International Convention 2024
Via AB Newswire
MAIA Biotechnology Inc (MAIA) Stock Surges as Company Prepares to Present Promising Data at BIO International Convention
Via AB Newswire
News headline image
MAIA Biotechnology's Unique Telomere Targeting Agent Currently In Clinical Development Shows Promise For The Multi-Billion Dollar Cancer Therapy Market
MAIA Biotechnology's Unique Telomere Targeting Agent Currently In Clinical Development Shows Promise For The Multi-Billion Dollar Cancer Therapy Market 
Via News Direct
MAIA Biotechnology (NYSE: MAIA) Makes Strategic Moves: Key Presentations, New Funding, and Leadership Changes Drive Innovation
Via AB Newswire
News headline image
MAIA Biotechnology to Present at the BIO International Convention 2024
From MAIA Biotechnology, Inc.
Via Business Wire
News headline image
MAIA Biotechnology Abstract Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
From MAIA Biotechnology, Inc.
Via Business Wire
News headline image
MAIA Stock Earnings: MAIA Biotechnology Misses EPS for Q1 2024 ↗
MAIA stock results show that MAIA Biotechnology missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement
From MAIA Biotechnology, Inc.
Via Business Wire
News headline image
MAIA Biotechnology Announces Share Purchase by Director Stan Smith, Ph.D. in Private Placement
From MAIA Biotechnology, Inc.
Via Business Wire
News headline image
MAIA Biotechnology Announces $1.00 Million Private Placement
From MAIA Biotechnology, Inc.
Via Business Wire
News headline image
MAIA Biotechnology to Present at Two Investor Conferences in April 2024
From MAIA Biotechnology, Inc.
Via Business Wire
News headline image
MAIA Biotechnology Announces Share Purchases by Directors Cristian Luput and Ramiro Guerrero
From MAIA Biotechnology, Inc.
Via Business Wire
News headline image
MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement
From MAIA Biotechnology, Inc.
Via Business Wire
News headline image
MAIA Biotechnology Announces $1.33 Million Private Placement
From MAIA Biotechnology, Inc.
Via Business Wire
News headline image
MAIA Biotechnology Announces Share Purchase by Director Stan Smith, PhD in a $2.9 Million Private Placement
From MAIA Biotechnology, Inc.
Via Business Wire
News headline image
MAIA Stock Earnings: MAIA Biotechnology Misses EPS for Q4 2023 ↗
MAIA stock results show that MAIA Biotechnology missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
MAIA Biotechnology Welcomes Prominent Medical Oncology Scientist Dr. Saadettin Kilickap to its Scientific Advisory Board
From MAIA Biotechnology, Inc.
Via Business Wire
News headline image
MAIA Biotechnology to Participate in the 36th Annual ROTH Conference
From MAIA Biotechnology, Inc.
Via Business Wire
News headline image
MAIA Biotechnology and Nationwide Children’s Hospital Announce Presentation of THIO’s Potency in Pediatric Brain Tumors at American Association of Cancer Research Annual Meeting
From MAIA Biotechnology, Inc.
Via Business Wire
News headline image
MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients
From MAIA Biotechnology, Inc.
Via Business Wire
News headline image
MAIA Biotechnology CEO Details Immuno-Oncology Cancer Treatment Candidates and Development Pipeline in Letter to Shareholders
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotech Completes Enrollment For Phase 2 Trial Of Its Candidate THIO To Fight Non-Small Cell Lung Cancer
--News Direct-- 
Via News Direct
News headline image
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential ↗
MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months. 
Via Talk Markets
News headline image
MAIA Biotechnology Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
News headline image
Novel Therapy Shows Promising Results In On-Going Trials, Receives 3 Orphan Drug Designations From The FDA ↗
Vlad Vitoc, MD, MBA; CEO & Chairman of MAIA Biotechnology (NYSE: MAIA), was a guest on Benzinga’s All Access. MAIA is a targeted therapy immuno-oncology company focused on developing and... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
MAIA Biotechnology Announces Publication of International PCT Patent Application Covering Anticancer Telomere-Targeting Compounds
From MAIA Biotechnology
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >